Navigation Links
ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
Date:10/20/2010

EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2010 are expected to be released on Wednesday, October 27, 2010 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2010 third quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until November 16, 2010.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please down
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Decision Resources ... anti-vascular endothelial growth factor (VEGF) agent for wet AMD, ... Medicare Advantage plans as Genentech,s Lucentis, which is the ... surveyed managed care organization (MCO) directors do not identify ... is slightly more likely than Lucentis to be listed ...
(Date:9/18/2014)... Sept. 18, 2014  ePharmaSolutions, the leading ... as the Disruptive Innovator of the Year ... eClinical platform. This solution includes an integrated ... file (eTMF), a remote monitoring application, eSource ... patient screening and matching technology. ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Asia-Pacific Dental Devices ... http://www.reportlinker.com/p0336613/Asia-Pacific-Dental-Devices-Market-Outlook-to-2016.html Asia-Pacific Dental Devices ... new report, "Asia-Pacific Dental Devices Market Outlook to ...
... 2010 Reportlinker.com announces that a new market research ... China Pharmaceutical Market Overview http://www.reportlinker.com/p0337367/China-Pharmaceutical-Market-Overview.html ... pharma market generated sales of $22.9 billion in 2009, ... and 2009. Key growth drivers include China,s support of ...
Cached Medicine Technology:Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 2Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 3Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 4Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 5Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 6Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 7Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 8Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 9Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 10Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 11Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 12Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 13Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 14Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 15Reportlinker Adds China Pharmaceutical Market Overview 2Reportlinker Adds China Pharmaceutical Market Overview 3Reportlinker Adds China Pharmaceutical Market Overview 4Reportlinker Adds China Pharmaceutical Market Overview 5Reportlinker Adds China Pharmaceutical Market Overview 6Reportlinker Adds China Pharmaceutical Market Overview 7Reportlinker Adds China Pharmaceutical Market Overview 8Reportlinker Adds China Pharmaceutical Market Overview 9Reportlinker Adds China Pharmaceutical Market Overview 10Reportlinker Adds China Pharmaceutical Market Overview 11Reportlinker Adds China Pharmaceutical Market Overview 12Reportlinker Adds China Pharmaceutical Market Overview 13Reportlinker Adds China Pharmaceutical Market Overview 14Reportlinker Adds China Pharmaceutical Market Overview 15Reportlinker Adds China Pharmaceutical Market Overview 16Reportlinker Adds China Pharmaceutical Market Overview 17
(Date:9/18/2014)... Luis Obispo, CA (PRWEB) September 18, 2014 ... Bootie introduced their newest, patent pending bunion splint to ... As one loyalist, Rosa, wrote: "I was absolutely delighted. It ... I honestly forget I am wearing them. THANK YOU FOR ... recently introduced design by saying, "The hole used to slip ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. ... a common antidepressant can quickly alter the way brain cells ... reported online Sept. 18 in Current Biology , ... widely prescribed antidepressants. Experts said the hope is to eventually ... to benefit from a drug -- and which people would ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... The effect of guidelines recommending that elderly men should ... minimal at best," according to a new study led ... as a research letter online in JAMA Internal ... prostate-specific antigen to test for prostate cancer., "We ... the routine screening of elderly men in particular has ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... Analytical, based in Ames, IA will reveal the latest results ... system. This instrument rapidly identifies microorganisms in less ... The generated fingerprint when compared to a database of ... strain typing and tracking.Because of its ease of use and ...
... 2009, the United States District Court for the Southern ... previously disclosed antitrust lawsuit filed by Pioneer Valley Casket ... casket retailers against Batesville Casket Company, Inc., a wholly ... )The Pioneer Valley plaintiffs agreed to dismiss their complaint ...
... Inc. (NYSE: DVA ) announced that the United ... has informed the company that it has completed its investigation ... was first issued a formal subpoena in October 2004 and ... against the company, no fines were assessed and no mandatory ...
... A new survey from Noblis Health Innovation, a ... context of the current economic crisis, nearly a third of hospitals ... Conducted in April 2009, the affiliation study is the first in ... Noblis Insights Panel , a collection of more than 150 leading ...
... make that dream so real, goes a popular song. Now ... to perform an essential form of DNA repair. , Prof. ... been studying DNA repair for some two decades: ,Considering that ... a day by radiation, pollutants and harmful chemicals produced within ...
... Cancer Screenings And Education about Skin Cancer PreventionSKILLMAN, N.J., ... Johnson Consumer Companies, Inc., announces its second year of ... Skin" tour. The free skin cancer screening tour ... New York City,s Grand Central Terminal, and will visit ...
Cached Medicine News:Health News:Advanced Analytical Reveals New Platform for Rapid Genotypic Identification of Microorganisms at ASM 2009 2Health News:Federal District Judge Dismisses Antitrust Lawsuit Against Batesville Casket Company 2Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 2Health News:Noblis Insights Panel Finds Growing Interest in Hospital Affiliation as a Strategic Response to Challenging Market Conditions 3Health News:Stopgap DNA repair needs a second step 2Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 3Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 4
Span Diagnostics Limited...
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Medicine Products: